PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Abstract Background Reliable noninvasive predictors of the top three causes of death [cardiovascular diseases (CVDs), malignancies, and liver-related events in patients with non-alcoholic fatty liver disease (NAFLD)] have not yet been determined. Methods We retrospectively investigated the incidence...

Full description

Bibliographic Details
Main Authors:	Norio Akuta, Yusuke Kawamura, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada
Format:	Article
Language:	English
Published:	BMC 2021-11-01
Series:	BMC Gastroenterology
Subjects:	Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Cardiovascular diseases Malignancies Liver-related events FIB-4 index
Online Access:	https://doi.org/10.1186/s12876-021-02020-z

Similar Items

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
by: Norio Akuta, et al.
Published: (2018-11-01)

The role of the microbiome in NAFLD and NASH
by: Aleksandra A Kolodziejczyk, et al.
Published: (2018-12-01)

Epidemiology and natural history of NAFLD
by: Della Corte Claudia, et al.
Published: (2015-01-01)

Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, Damien, et al.
Published: (2023)

Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
by: Ankoor H. Patel, et al.
Published: (2024-07-01)

An Update on the Chemokine System in the Development of NAFLD
by: Naoto Nagata, et al.
Published: (2022-06-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients
by: Pathik Parikh, et al.
Published: (2016-01-01)

Noninvasive Diagnosis of NAFLD and NASH
by: Valeria Annarita Piazzolla, et al.
Published: (2020-04-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Non-alcoholic fatty liver disease: A review with clinical and pathological correlation
by: Yen-Ying Chen, et al.
Published: (2021-01-01)

Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
by: Marielle Malucelli, et al.
Published: (2023-11-01)

Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
by: Wasitha P. D. W. Thilakarathna, et al.
Published: (2024-02-01)

Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways
by: Glenn S. Gerhard, et al.
Published: (2018-07-01)

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome
by: Shunichiro Fujiyama, et al.
Published: (2017-10-01)

Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
by: Man Wang, et al.
Published: (2022-10-01)

Identifying Autophagy-Related lncRNAs and Potential ceRNA Networks in NAFLD
by: Ziyi Cao, et al.
Published: (2022-06-01)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01)

Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S]
by: D.Lee Gorden, et al.
Published: (2015-03-01)

Peripheral immune cells in NAFLD patients: A spyhole to disease progression
by: Shuang-Zhe Lin, et al.
Published: (2022-01-01)

Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)
by: Naveen Kalra, et al.
Published: (2009-01-01)

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
by: Norio Akuta, et al.
Published: (2020-01-01)

Nonalcoholic fatty liver disease
by: Lafaine M. Grant, et al.
Published: (2004-07-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact
by: David Højland Ipsen, et al.
Published: (2021-01-01)

Recent research trends and updates on nonalcoholic fatty liver disease
by: Jeong-Ju Yoo, et al.
Published: (2019-03-01)

Treatment Options in Non-alcoholic Fatty Liver Disease
by: Won Kim
Published: (2017-06-01)

Disease Progression in a Patient with Nonalcoholic Steatohepatitis
by: Ping-Huei Tseng, et al.
Published: (2008-10-01)

Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease
by: Marek Waluga, et al.
Published: (2017-09-01)

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
by: V.N. Santos, et al.
Published: (2003-06-01)

Metabolically associated fatty liver disease – a disease of the 21st century: A review
by: Igor V. Maev, et al.
Published: (2022-07-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients
by: Rodrigo Vieira Costa Lima, et al.
Published: (2021-11-01)

Comparative Transcriptomics Analyses in Livers of Mice, Humans, and Humanized Mice Define Human-Specific Gene Networks
by: Chengfei Jiang, et al.
Published: (2020-11-01)

Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019
by: Juan Pang, et al.
Published: (2022-08-01)

Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients
by: Haghpanah Babak, et al.
Published: (2003-10-01)

Male LEW.1WR1 Rats Develop Metabolic Dysfunction, Steatohepatitis, and Liver Damage
by: Quiana C. Wilkerson-Vidal, et al.
Published: (2024-04-01)

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by: Reeju Amatya, et al.
Published: (2023-07-01)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
by: Margaret LP Teng, et al.
Published: (2023-04-01)

ADEMETHIONINE IN THERAPY OF NON-ALCOHOLIC FATTY LIVER DISEASE
by: A. V. Polukhina, et al.
Published: (2017-11-01)